Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. Kris MG, Faivre-Finn C, Kordbacheh T, Chaft J, Luo J, Tsao A, et al. Making checkpoint inhibitors part of treatment of patients with locally advanced lung cancers: the time is now. Am Soc Clin Oncol Educ Book. 2020;40:1–12.
2. Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:786–95.
3. Wu YL, Herbst RS, Mann H, Rukazenkov Y, Marotti M, Tsuboi M. ADAURA: phase III, double-blind, randomized study of osimertinib versus PBO in EGFR mutation-positive early-stage NSCLC after complete surgical resection. Clin Lung Cancer. 2018;19:e533–6.
4. Casiraghi M, Bertolaccini L, Sedda G, Petrella F, Galetta D, Guarize J, et al. Lung cancer surgery in oligometastatic patients: outcome and survival. Eur J Cardiothorac Surg. 2020;57:1173–80.
5. Suzawa K, Soh J, Takahashi Y, Sato H, Shien K, Yamamoto H, et al. Clinical outcome of patients with recurrent non-small cell lung cancer after trimodality therapy. Surg Today. 2019;49:601–9.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献